Anocca Raises SEK 400 Million for Large-Scale Development of Cancer Cell Therapies
Details : The financing will develop the company's unique process that enables discovery and manufacture of next generation TCR-T-based cell therapies for cancer on an industrial scale. The financing also allows Anocca to progress the company's first products into...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 31, 2023
Dong-A ST and Beactica Therapeutics Mutually Agree to Conclude Oncology Collaboration
Details : As part of the termination, both Dong-A ST and Beactica Therapeutics will gain exclusive global rights for further development and commercialization for different compounds series developed during the collaboration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 09, 2022
Details : Under the terms of the agreement, Oscotec is entitled to gain exclusive global rights for further development and commercialization of Beactica's programme.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 03, 2021